These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 12618880)

  • 1. Molecular analysis of local relapse in high-risk breast cancer patients: can radiotherapy fractionation and time factors make a difference?
    Koukourakis MI; Giatromanolaki A; Galazios G; Sivridis E
    Br J Cancer; 2003 Mar; 88(5):711-7. PubMed ID: 12618880
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
    Koukourakis MI; Giatromanolaki A; Kouroussis C; Kakolyris S; Sivridis E; Frangiadaki C; Retalis G; Georgoulias V;
    Int J Radiat Oncol Biol Phys; 2002 Jan; 52(1):144-55. PubMed ID: 11777632
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 and c-erbB-2 but not bcl-2 are predictive of metastasis-free survival in breast cancer patients receiving post-mastectomy adjuvant radiotherapy in Taiwan.
    Chen HH; Su WC; Guo HR; Chang TW; Lee WY
    Jpn J Clin Oncol; 2002 Sep; 32(9):332-9. PubMed ID: 12417598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of p53, glutathione S-transferase-pi, and Bcl-2 proteins and benefit from adjuvant radiotherapy in breast cancer.
    Silvestrini R; Veneroni S; Benini E; Daidone MG; Luisi A; Leutner M; Maucione A; Kenda R; Zucali R; Veronesi U
    J Natl Cancer Inst; 1997 May; 89(9):639-45. PubMed ID: 9150188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer.
    Koukourakis MI
    Semin Oncol; 2002 Dec; 29(6 Suppl 19):42-6. PubMed ID: 12577243
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of p53 and bcl-2 expression in patients treated with breast conservative therapy.
    Kim K; Chie EK; Han W; Noh DY; Park IA; Oh DY; Im SA; Kim TY; Bang YJ; Ha SW
    J Korean Med Sci; 2010 Feb; 25(2):235-9. PubMed ID: 20119576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bax protein expression in colorectal cancer: association with p53, bcl-2 and patterns of relapse.
    Giatromanolaki A; Sivridis E; Stathopoulos GP; Fountzilas G; Kalofonos HP; Tsamandas A; Vrettou E; Scopa C; Polychronidis A; Simopoulos K; Koukourakis MI
    Anticancer Res; 2001; 21(1A):253-9. PubMed ID: 11299743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer.
    Rozan S; Vincent-Salomon A; Zafrani B; Validire P; De Cremoux P; Bernoux A; Nieruchalski M; Fourquet A; Clough K; Dieras V; Pouillart P; Sastre-Garau X
    Int J Cancer; 1998 Feb; 79(1):27-33. PubMed ID: 9495354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins.
    Zhang GJ; Tsuda H; Adachi I; Fukutomi T; Yamamoto H; Hirohashi S
    Jpn J Clin Oncol; 1997 Dec; 27(6):371-7. PubMed ID: 9437997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypofractionated and accelerated radiotherapy with subcutaneous amifostine cytoprotection as short adjuvant regimen after breast-conserving surgery: interim report.
    Koukourakis MI; Tsoutsou PG; Abatzoglou IM; Sismanidou K; Giatromanolaki A; Sivridis E
    Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1173-80. PubMed ID: 19058920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of highly angiogenic and disseminated in the peripheral blood disease in breast cancer patients predicts for resistance to adjuvant chemotherapy and early relapse.
    Giatromanolaki A; Koukourakis MI; Kakolyris S; Mavroudis D; Kouroussis C; Mavroudi C; Perraki M; Sivridis E; Georgoulias V
    Int J Cancer; 2004 Feb; 108(4):620-7. PubMed ID: 14696130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis.
    Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Chikhlikar PR; Ghosh N; Trivedi TI
    Ann Surg Oncol; 2000 May; 7(4):305-11. PubMed ID: 10819372
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2 protein expression is associated with p27 and p53 protein expressions and MIB-1 counts in breast cancer.
    Tsutsui S; Yasuda K; Suzuki K; Takeuchi H; Nishizaki T; Higashi H; Era S
    BMC Cancer; 2006 Jul; 6():187. PubMed ID: 16839413
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The contribution of molecular markers to the prediction of response in the treatment of breast cancer: a review of the literature on HER-2, p53 and BCL-2.
    Hamilton A; Piccart M
    Ann Oncol; 2000 Jun; 11(6):647-63. PubMed ID: 10942052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High dose daily amifostine and hypofractionated intensively accelerated radiotherapy for locally advanced breast cancer. A phase I/II study and report on early and late sequellae.
    Koukourakis MI; Yannakakis D
    Anticancer Res; 2001; 21(4B):2973-8. PubMed ID: 11712796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postmastectomy hypofractionated and accelerated radiation therapy with (and without) subcutaneous amifostine cytoprotection.
    Koukourakis MI; Panteliadou M; Abatzoglou IM; Sismanidou K; Sivridis E; Giatromanolaki A
    Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e7-13. PubMed ID: 23040218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. c-erbB-2 oncoprotein is overexpressed in poorly vascularised squamous cell carcinomas of the head and neck, but is not associated with response to cytotoxic therapy or survival.
    Giatromanolaki A; Koukourakis MI; Sivridis E; Fountzilas G
    Anticancer Res; 2000; 20(2A):997-1004. PubMed ID: 10810387
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
    Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
    Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients.
    Isola J; Visakorpi T; Holli K; Kallioniemi OP
    J Natl Cancer Inst; 1992 Jul; 84(14):1109-14. PubMed ID: 1352359
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.